Piper Jaffray Assumes Biogen (BIIB) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil rises as renewed US-Iran strikes stoke supply fears
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM EDTBiogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS). The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.
These data... More
UPDATE: Citi Downgrades Biogen (BIIB) to Neutral
October 23, 2017 6:26 AM EDT(Updated - October 23, 2017 7:17 AM EDT)
(updated to add analyst comment)
Citi downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $360.00 (from $320.00).
Analyst Robyn Karnauskas says the SMA thesis is largely baked into the stock... More
